Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Alberto Pérez Rubio & Jose María Eiros. (2018) Cell culture-derived flu vaccine: Present and future. Human Vaccines & Immunotherapeutics 14:8, pages 1874-1882.
Read now
Read now
Stephan Bart, Kevin Cannon, Darrell Herrington, Richard Mills, Eduardo Forleo-Neto, Kelly Lindert & Ahmed Abdul Mateen. (2016) Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study. Human Vaccines & Immunotherapeutics 12:9, pages 2278-2288.
Read now
Read now
Ilaria Manini, Alexander Domnich, Daniela Amicizia, Stefania Rossi, Teresa Pozzi, Roberto Gasparini, Donatella Panatto & Emanuele Montomoli. (2015) Flucelvax (Optaflu) for seasonal influenza. Expert Review of Vaccines 14:6, pages 789-804.
Read now
Read now
Nagendra R Hegde. (2015) Cell culture-based influenza vaccines: A necessary and indispensable investment for the future. Human Vaccines & Immunotherapeutics 11:5, pages 1223-1234.
Read now
Read now
Articles from other publishers (7)
Karen Jordan, Eamon O. Murchu, Laura Comber, Sarah Hawkshaw, Liam Marshall, Michelle O’Neill, Conor Teljeur, Patricia Harrington, Annasara Carnahan, Jaime Jesús Pérez‐Martín, Anna Hayman Robertson, Kari Johansen, Jorgen de Jonge, Tyra Krause, Nathalie Nicolay, Hanna Nohynek, Ioanna Pavlopoulou, Richard Pebody, Pasi Penttinen, Marta Soler‐Soneira, Ole Wichmann & Máirín Ryan. (2022) Systematic review of the efficacy, effectiveness and safety of cell‐based seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age. Reviews in Medical Virology 33:3.
Crossref
Crossref
Yvette N. Lamb. (2019) Cell-Based Quadrivalent Inactivated Influenza
Virus Vaccine (Flucelvax® Tetra/Flucelvax
Quadrivalent®): A Review in the Prevention of
Influenza. Drugs 79:12, pages 1337-1348.
Crossref
Crossref
Surender Khurana, Megan Hahn, Elizabeth M. Coyle, Lisa R. King, Tsai-Lien Lin, John Treanor, Andrea Sant & Hana Golding. (2019) Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans. Nature Communications 10:1.
Crossref
Crossref
Micha Loebermann, Carlos Fritzsche, Hilte Geerdes-Fenge, Esther Heijnen, Daniel Kirby & Emil C. Reisinger. (2018) A phase III, open-label, single-arm, study to evaluate the safety and immunogenicity of a trivalent, surface antigen inactivated subunit influenza virus vaccine produced in mammalian cell culture (Optaflu®) in healthy adults. Infection 47:1, pages 105-109.
Crossref
Crossref
Donald Y.M. Leung, Brett Jepson, Lisa A. Beck, Jon M. Hanifin, Lynda C. Schneider, Amy S. Paller, Katherine Monti, Gloria David, Jennifer Canniff, Margarita Gomez Lorenzo & Adriana Weinberg. (2017) A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology 139:5, pages 1575-1582.e8.
Crossref
Crossref
V.H. Basavaraj, G. Sampath, Nagendra R. Hegde, V. Krishna Mohan & Krishna M. Ella. (2014) Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies. Vaccine 32:35, pages 4592-4597.
Crossref
Crossref
Christopher Stobart & Martin Moore. (2014) RNA Virus Reverse Genetics and Vaccine Design. Viruses 6:7, pages 2531-2550.
Crossref
Crossref